Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours

@inproceedings{Doi2012PhaseIS,
  title={Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours},
  author={Toshihiko Doi and Atsushi Ohtsu and Takayuki Yoshino and Narikazu Boku and Yusuke Onozawa and Akira Fukutomi and Shuichi Hironaka and Wasaburo Koizumi and Tohru Sasaki},
  booktitle={British Journal of Cancer},
  year={2012}
}
Background:TAS-102 consists of α, α, α-trifluorothymidine (TFT) and an inhibitor of thymidine phosphorylase (TPI). We conducted a dose-escalation phase I study in Japanese patients with advanced solid tumours.Methods:TAS-102 was administered twice daily on days 1–5 and days 8–12 in a 28-day cycle to patients with solid tumours refractory to standard chemotherapy, to determine its maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetics (PKs). MTD was evaluated in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Therapeutic potential of the dual - targeted TAS - 102 formulation in the treatment of gastrointestinal malignancies

  • OH Temmink, T Emura, M deBruin, M Fukushima, GJ Peters
  • Cancer Sci
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…